腦腫瘤藥物市場：按治療類型、適應症、分銷管道分類 - 全球預測 2023-2030

預計到 2023 年，全球腦腫瘤治療市場將達到 203315 萬美元，年複合成長率7.41%，預計到 2030 年將成長至驚人的 335783 萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球腦腫瘤治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球腦腫瘤治療藥物市場規模及預測如何？

2.在預測期內，COVID-19對全球腦腫瘤治療藥物市場的阻礙因素與影響為何？

3.在預測期內，全球腦腫瘤藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球腦腫瘤藥物市場的競爭策略為何？

5.全球腦腫瘤藥物市場的技術趨勢和法律規範是什麼？

6.全球腦瘤治療藥物市場主要廠商的市佔率如何？

7. 哪些型態和策略措施被認為適合進入腦腫瘤藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 久坐的生活方式導致腦腫瘤的罹患率增加
    • 患有神經系統疾病的老年人口迅速增加
    • 提高患者對治療可用性的認知
  • 抑制因素
    • 使用標靶治療阻止癌症生長
  • 機會
    • 政府和製藥公司在藥物開發方面的積極努力
    • 奈米粒子藥物傳輸等領域穩定發展
  • 任務
    • 批准這些藥物的嚴格法規指南
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 依治療類型分類的腦腫瘤藥物市場

• 化學處理
• 免疫療法
• 標靶治療

第7章 依適應症分類的腦腫瘤藥物市場

• 膠質母細胞瘤
• 腦膜瘤
• 腦下垂體瘤

第8章 腦腫瘤治療藥物市場：按分銷管道

• 醫院藥房
• 零售藥房

第9章 美洲腦腫瘤藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章 亞太腦腫瘤藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章歐洲、中東和非洲腦腫瘤藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

• 討論指南
• 關於許可證和定價

The Global Brain Cancer Drugs Market is forecasted to grow significantly, with a projected USD 2,033.15 million in 2023 at a CAGR of 7.41% and expected to reach a staggering USD 3,357.83 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Brain Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Brain Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapy Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Glioblastoma, Meningioma, and Pituitary Tumors. The Pituitary Tumors is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy and Retail pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Brain Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Brain Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Brain Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Brain Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Brain Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Brain Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Brain Cancer Drugs Market, by Therapy Type, 2022 vs 2030
• 4.3. Brain Cancer Drugs Market, by Indication, 2022 vs 2030
• 4.4. Brain Cancer Drugs Market, by Distribution Channel, 2022 vs 2030
• 4.5. Brain Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of brain cancer with sedentary lifestyles
    • 5.1.1.2. Surge in geriatric population suffering from neurological disorders
    • 5.1.1.3. Rising patient awareness on the availability of treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Use of targeted therapies to block cancer growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable initiatives from government and pharmaceutical companies in the development of the drug
    • 5.1.3.2. Robust development in areas such as use of nanoparticles to carry drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Strict regulatory guidelines in the approval of these drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Brain Cancer Drugs Market, by Therapy Type

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Targeted Therapy

7. Brain Cancer Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Glioblastoma
• 7.3. Meningioma
• 7.4. Pituitary Tumors

8. Brain Cancer Drugs Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Retail pharmacy

9. Americas Brain Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Brain Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. BRAIN CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. BRAIN CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2022 VS 2030 (%)
• FIGURE 5. BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 6. BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. BRAIN CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. BRAIN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 9. BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 13. BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. CANADA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. INDIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. ITALY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. POLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. QATAR BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 143. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 144. BRAIN CANCER DRUGS MARKET LICENSE & PRICING